Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBIT Margin (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of EBIT Margin data on record, last reported at 2169.55% in Q4 2025.

  • For Q4 2025, EBIT Margin changed N/A year-over-year to 2169.55%; the TTM value through Dec 2025 reached 6714.77%, up 2589870.0%, while the annual FY2025 figure was 6714.77%, 2589870.0% up from the prior year.
  • EBIT Margin reached 2169.55% in Q4 2025 per CRNX's latest filing, up from 99710.49% in the prior quarter.
  • Across five years, EBIT Margin topped out at 1080.39% in Q1 2022 and bottomed at 99710.49% in Q3 2025.
  • Average EBIT Margin over 5 years is 16546.14%, with a median of 9646.51% recorded in 2022.
  • The widest YoY moves for EBIT Margin: up 822463bps in 2025, down -1937120bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 2865.31% in 2021, then crashed by -134bps to 6707.48% in 2022, then tumbled by -154bps to 17045.38% in 2023, then fell by -22bps to 20747.62% in 2024, then surged by 90bps to 2169.55% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 2169.55% in Q4 2025, 99710.49% in Q3 2025, and 12522.99% in Q2 2025.